324 related articles for article (PubMed ID: 24418122)
1. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.
Poels EM; Kegeles LS; Kantrowitz JT; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
Schizophr Res; 2014 Feb; 152(2-3):325-32. PubMed ID: 24418122
[TBL] [Abstract][Full Text] [Related]
2. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.
Poels EM; Kegeles LS; Kantrowitz JT; Slifstein M; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
Mol Psychiatry; 2014 Jan; 19(1):20-9. PubMed ID: 24166406
[TBL] [Abstract][Full Text] [Related]
3. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.
Merritt K; McGuire PK; Egerton A; ; Aleman A; Block W; Bloemen OJN; Borgan F; Bustillo JR; Capizzano AA; Coughlin JM; De la Fuente-Sandoval C; Demjaha A; Dempster K; Do KQ; Du F; Falkai P; Galinska-Skok B; Gallinat J; Gasparovic C; Ginestet CE; Goto N; Graff-Guerrero A; Ho BC; Howes OD; Jauhar S; Jeon P; Kato T; Kaufmann CA; Kegeles LS; Keshavan M; Kim SY; Kunugi H; Lauriello J; Liemburg EJ; Mcilwain ME; Modinos G; Mouchlianitis ED; Nakamura J; Nenadic I; Öngür D; Ota M; Palaniyappan L; Pantelis C; Plitman E; Posporelis S; Purdon SE; Reichenbach JR; Renshaw PF; Russell BR; Sawa A; Schaefer M; Shungu DC; Smesny S; Stanley JA; Stone JM; Szulc A; Taylor R; Thakkar K; Théberge J; Tibbo PG; van Amelsvoort T; Walecki J; Williamson PC; Wood SJ; Xin L; Yamasue H
JAMA Psychiatry; 2021 Jun; 78(6):667-681. PubMed ID: 33881460
[TBL] [Abstract][Full Text] [Related]
4. Glutamate in dorsolateral prefrontal cortex and auditory verbal hallucinations in patients with schizophrenia: A
Ćurčić-Blake B; Bais L; Sibeijn-Kuiper A; Pijnenborg HM; Knegtering H; Liemburg E; Aleman A
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():132-139. PubMed ID: 28546056
[TBL] [Abstract][Full Text] [Related]
5. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.
Bustillo JR; Chen H; Jones T; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C
JAMA Psychiatry; 2014 Mar; 71(3):265-72. PubMed ID: 24402128
[TBL] [Abstract][Full Text] [Related]
6. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
Merritt K; Egerton A; Kempton MJ; Taylor MJ; McGuire PK
JAMA Psychiatry; 2016 Jul; 73(7):665-74. PubMed ID: 27304221
[TBL] [Abstract][Full Text] [Related]
7. Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia.
Jelen LA; King S; Mullins PG; Stone JM
J Psychopharmacol; 2018 May; 32(5):497-508. PubMed ID: 29368979
[TBL] [Abstract][Full Text] [Related]
8. Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.
Plitman E; de la Fuente-Sandoval C; Reyes-Madrigal F; Chavez S; Gómez-Cruz G; León-Ortiz P; Graff-Guerrero A
Schizophr Bull; 2016 Mar; 42(2):415-24. PubMed ID: 26320195
[TBL] [Abstract][Full Text] [Related]
9. Using proton magnetic resonance spectroscopic imaging to study glutamatergic alterations in patients with schizophrenia: A systematic review.
Plitman E; Guma E; Lepage M; Near J; Chakravarty MM
Schizophr Res; 2019 Aug; 210():13-20. PubMed ID: 31272905
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism.
Duarte JMN; Xin L
Neurochem Res; 2019 Jan; 44(1):102-116. PubMed ID: 29616444
[TBL] [Abstract][Full Text] [Related]
11. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.
Marsman A; van den Heuvel MP; Klomp DW; Kahn RS; Luijten PR; Hulshoff Pol HE
Schizophr Bull; 2013 Jan; 39(1):120-9. PubMed ID: 21746807
[TBL] [Abstract][Full Text] [Related]
12. Effect of L-theanine on glutamatergic function in patients with schizophrenia.
Ota M; Wakabayashi C; Sato N; Hori H; Hattori K; Teraishi T; Ozawa H; Okubo T; Kunugi H
Acta Neuropsychiatr; 2015 Oct; 27(5):291-6. PubMed ID: 25896423
[TBL] [Abstract][Full Text] [Related]
13. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of
Nakahara T; Tsugawa S; Noda Y; Ueno F; Honda S; Kinjo M; Segawa H; Hondo N; Mori Y; Watanabe H; Nakahara K; Yoshida K; Wada M; Tarumi R; Iwata Y; Plitman E; Moriguchi S; de la Fuente-Sandoval C; Uchida H; Mimura M; Graff-Guerrero A; Nakajima S
Mol Psychiatry; 2022 Jan; 27(1):744-757. PubMed ID: 34584230
[TBL] [Abstract][Full Text] [Related]
14. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.
Iwata Y; Nakajima S; Plitman E; Caravaggio F; Kim J; Shah P; Mar W; Chavez S; De Luca V; Mimura M; Remington G; Gerretsen P; Graff-Guerrero A
Biol Psychiatry; 2019 Apr; 85(7):596-605. PubMed ID: 30389132
[TBL] [Abstract][Full Text] [Related]
15. Decoupling of N-acetyl-aspartate and glutamate within the dorsolateral prefrontal cortex in schizophrenia.
Coughlin JM; Tanaka T; Marsman A; Wang H; Bonekamp S; Kim PK; Higgs C; Varvaris M; Edden RA; Pomper M; Schretlen D; Barker PB; Sawa A
Curr Mol Med; 2015; 15(2):176-83. PubMed ID: 25732147
[TBL] [Abstract][Full Text] [Related]
16. Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.
Natsubori T; Inoue H; Abe O; Takano Y; Iwashiro N; Aoki Y; Koike S; Yahata N; Katsura M; Gonoi W; Sasaki H; Takao H; Kasai K; Yamasue H
Schizophr Bull; 2014 Sep; 40(5):1128-39. PubMed ID: 24023251
[TBL] [Abstract][Full Text] [Related]
17. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).
Tayoshi S; Sumitani S; Taniguchi K; Shibuya-Tayoshi S; Numata S; Iga J; Nakataki M; Ueno S; Harada M; Ohmori T
Schizophr Res; 2009 Mar; 108(1-3):69-77. PubMed ID: 19097753
[TBL] [Abstract][Full Text] [Related]
18. 1H-MRS at 4 tesla in minimally treated early schizophrenia.
Bustillo JR; Rowland LM; Mullins P; Jung R; Chen H; Qualls C; Hammond R; Brooks WM; Lauriello J
Mol Psychiatry; 2010 Jun; 15(6):629-36. PubMed ID: 19918243
[TBL] [Abstract][Full Text] [Related]
19. Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study.
Soeiro-de-Souza MG; Otaduy MCG; Machado-Vieira R; Moreno RA; Nery FG; Leite C; Lafer B
Biol Psychiatry Cogn Neurosci Neuroimaging; 2018 Dec; 3(12):985-991. PubMed ID: 29789269
[TBL] [Abstract][Full Text] [Related]
20. Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation.
Ota M; Ishikawa M; Sato N; Hori H; Sasayama D; Hattori K; Teraishi T; Nakata Y; Kunugi H
Acta Psychiatr Scand; 2012 Jul; 126(1):72-8. PubMed ID: 22432602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
